AcelRx Pharmaceuticals (ACRX) Receives Consensus Rating of “Hold” from Brokerages

Shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) have been assigned a consensus rating of “Hold” from the nine research firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $5.00.

Separately, Zacks Investment Research raised shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.25 price target on the stock in a report on Wednesday, December 27th.

An institutional investor recently bought a new position in AcelRx Pharmaceuticals stock. Virtu Financial LLC purchased a new stake in shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 59,184 shares of the specialty pharmaceutical company’s stock, valued at approximately $120,000. Virtu Financial LLC owned 0.12% of AcelRx Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 9.20% of the company’s stock.

Shares of AcelRx Pharmaceuticals (ACRX) traded down $0.03 during trading on Friday, reaching $2.05. 121,195 shares of the company’s stock were exchanged, compared to its average volume of 435,496. The company has a market cap of $101.80, a price-to-earnings ratio of -1.82 and a beta of 2.58. AcelRx Pharmaceuticals has a 1-year low of $1.55 and a 1-year high of $5.75. The company has a debt-to-equity ratio of -0.31, a quick ratio of 4.57 and a current ratio of 4.64.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last announced its quarterly earnings results on Thursday, March 8th. The specialty pharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.20). The firm had revenue of $0.74 million during the quarter, compared to the consensus estimate of $2.90 million. sell-side analysts expect that AcelRx Pharmaceuticals will post -0.98 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “AcelRx Pharmaceuticals (ACRX) Receives Consensus Rating of “Hold” from Brokerages” was first reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Analyst Recommendations for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply